Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by State of Tennessee Department of Treasury

State of Tennessee Department of Treasury grew its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) by 4.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 70,502 shares of the company’s stock after acquiring an additional 3,003 shares during the quarter. State of Tennessee Department of Treasury’s holdings in Cytek Biosciences were worth $458,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. grew its position in Cytek Biosciences by 58.3% during the 4th quarter. JPMorgan Chase & Co. now owns 947,683 shares of the company’s stock worth $6,150,000 after purchasing an additional 349,146 shares during the last quarter. Royce & Associates LP grew its holdings in shares of Cytek Biosciences by 159.6% during the fourth quarter. Royce & Associates LP now owns 470,819 shares of the company’s stock valued at $3,056,000 after buying an additional 289,425 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Cytek Biosciences by 16.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,830,432 shares of the company’s stock valued at $11,880,000 after acquiring an additional 262,607 shares during the period. Renaissance Technologies LLC raised its stake in Cytek Biosciences by 118.6% in the 4th quarter. Renaissance Technologies LLC now owns 462,600 shares of the company’s stock worth $3,002,000 after acquiring an additional 251,000 shares during the last quarter. Finally, Barclays PLC lifted its position in Cytek Biosciences by 333.6% during the 3rd quarter. Barclays PLC now owns 201,359 shares of the company’s stock worth $1,116,000 after acquiring an additional 154,915 shares during the period. Institutional investors and hedge funds own 69.46% of the company’s stock.

Cytek Biosciences Trading Up 4.3 %

Shares of CTKB opened at $3.86 on Friday. The firm has a market cap of $494.45 million, a P/E ratio of -48.24 and a beta of 1.41. The stock’s 50 day moving average is $4.00 and its two-hundred day moving average is $5.31. Cytek Biosciences, Inc. has a 12 month low of $3.27 and a 12 month high of $7.63.

Analysts Set New Price Targets

A number of brokerages recently commented on CTKB. The Goldman Sachs Group set a $5.25 target price on Cytek Biosciences in a research report on Sunday, February 2nd. Stephens reaffirmed an “overweight” rating and issued a $6.00 price objective on shares of Cytek Biosciences in a report on Wednesday, March 19th. Finally, Piper Sandler reduced their target price on shares of Cytek Biosciences from $8.50 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, March 4th.

Cytek Biosciences Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.